<DOC>
	<DOCNO>NCT00424294</DOCNO>
	<brief_summary>To evaluate efficacy , safety tolerability CP-195543 celecoxib dual therapy subject rheumatoid arthritis</brief_summary>
	<brief_title>A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description>Trial enrollment prematurely discontinue December 3 , 2007 . The result interim efficacy safety analysis demonstrate overall poor tolerability profile high discontinuation rate dual therapy CP-195543 Celecoxib administer . The decision discontinue enrollment trial base efficacy serious safety concern . Previously enrol study participant continue study trial complete February 27 , 2008 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>A diagnosis RA base upon American college Rheumatology 1987 revise criterion Active disease Screening Stable dose methotrexate 1025 mg/week oral parenteral A diagnosis inflammatory secondary , noninflammatory arthritis , opinion Investigator , would interfere disease activity assessments A history hypersensitivity allergic type reaction cyclooxygenase inhibitor , opiate , aspirin sulfonamide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>